CN113354738B - Fusion toxin VEGF 165b mGEL and its coding gene and application - Google Patents

Fusion toxin VEGF 165b mGEL and its coding gene and application Download PDF

Info

Publication number
CN113354738B
CN113354738B CN202010145502.9A CN202010145502A CN113354738B CN 113354738 B CN113354738 B CN 113354738B CN 202010145502 A CN202010145502 A CN 202010145502A CN 113354738 B CN113354738 B CN 113354738B
Authority
CN
China
Prior art keywords
vegf
mgel
lys
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010145502.9A
Other languages
Chinese (zh)
Other versions
CN113354738A (en
Inventor
孙红琰
邵帅
刘海昌
胡栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shao Shuai
Sun Hongyan
Zhejiang Yuchang Biotechnology Co ltd
Original Assignee
Shaoxing Defanghua Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaoxing Defanghua Biotechnology Co ltd filed Critical Shaoxing Defanghua Biotechnology Co ltd
Priority to CN202010145502.9A priority Critical patent/CN113354738B/en
Publication of CN113354738A publication Critical patent/CN113354738A/en
Application granted granted Critical
Publication of CN113354738B publication Critical patent/CN113354738B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a fusion toxin VEGF 165b The mGEL and its coding gene and application belong to the field of biological pharmacy. Fusion toxin VEGF provided 165b /mGEL comprises VEGF 165 Inhibitory splice isoforms VEGF 165b Together with Gelonin mutant mGEL, it inhibits neovascularization and destroys neovascularization. The fusion toxin can be used as an active component to prepare medicines for treating various neovascular dependent diseases such as malignant tumor, neovascular eye diseases and the like, and can play an important role in the fields of medicine and biological pharmacy.

Description

FusionToxin VEGF 165b mGEL and its coding gene and application
Technical Field
The invention belongs to the field of biological pharmacy, and particularly relates to fusion toxin VEGF 165b /mGEL and coding gene and application thereof, in particular to VEGF 165 An inhibitory splice isomer and gelonin mutant fusion toxin, a coding gene, a preparation method and application thereof, in particular to application in treating neovascular dependence diseases such as malignant tumor, neovascular eye disease and the like.
Background
The angiogenesis-dependent diseases are a general term for a series of diseases including malignant tumors (e.g., lung cancer, gastrointestinal cancer, etc.), ocular neovascular diseases (e.g., wet macular degeneration, etc.), and the like. Malignant tumor growth depends on neovascularization, and if nutrition is obtained only by diffusion, the size of the tumor can not exceed 2mm 3 And thus will be at rest. However, tumor cells promote peripheral neovascularization during growth by autocrine of various cytokines. Before the new blood vessels grow in, the tumor grows linearly; after the new blood vessels grow in, the tumor grows exponentially. Therefore, inhibiting angiogenesis or destroying existing neovascular networks is equivalent to cutting off the nutrient supply of tumors, stopping the growth, keeping the tumors in a 'dormant' state, and finally eliminating the tumors by organisms after atrophy, apoptosis and necrosis.
Ocular neovascular diseases mainly include corneal neovascular hyperplasia and iris neovascular hyperplasia: (1) normal cornea has no blood vessels, and under the pathological conditions of wearing corneal contact lenses, ocular trauma, infectious and immune eye diseases and the like, blood capillaries invade from a corneal limbus vascular network to form corneal neovessels. Corneal neovascularization is structurally fragile, permeable and often blinding due to bleeding, exudation and secondary fibrosis. (2) Iris neovascularization is often followed by diseases of other parts of the eye such as central retinal vein occlusion, diabetes and the like and systemic diseases, and is a common cause of blindness and eyeball removal. Retinopathy is complicated by about 50% of diabetic patients with a history of more than ten years. Therefore, the eye disease of the neovascular eye can be effectively controlled and treated by inhibiting the generation of the neovascular or destroying the existing neovascular network.
Vascular endothelial cell growth factor (VEGF) and its receptor (VEGFR) family play an important role in the process of neovascularization, and are important targets for drug design. Human VEGF produces several different isoforms due to mRNA splicing, i.e., VEGF 121 、VEGF 165 、VEGF 189 And VEGF 208 Wherein VEGF 121 And VEGF 165 Is soluble cytokine, and has effects in promoting proliferation of vascular endothelial cells, angiogenesis, increasing vascular permeability, and accelerating blood flow. VEGFR, particularly VEGFR2, is a biomarker for neovascular endothelial cells with high specificity, and is highly expressed on the surface of neovascular endothelial cells, but very low or almost undetectable in the expression level of vascular endothelial cells in normal tissues.
It has been shown that differential splicing of the VEGF gene results in the production of VEGF that promotes angiogenesis xxx And VEGF inhibiting angiogenesis xxxb . In VEGF xxxb In family, VEGF 165b Most typically, it antagonizes VEGF on the one hand by binding with high affinity to VEGFR 165 The binding of the vascular endothelial growth factor and the receptor thereof can not activate the signal transduction pathway in the vascular endothelial cells, so that the vascular endothelial growth factor becomes a VEGF antagonist and plays a role in inhibiting the proliferation and angiogenesis of the neovascular endothelial cells.
Currently, the targeted drugs of vascular endothelial growth factor and its receptor are mainly divided into two categories: one is angiogenesis inhibitor, which only inhibits angiogenesis but can not destroy existing new vessels, such as bevacizumab and engdu; another class is neovascular disruptors, i.e., agents that treat diseases such as tumors by recognizing and disrupting existing neovascular networks, e.g., VEGFR-targeted fusion toxins, reported to be predominantly VEGF 165 /DT390、VEGF 121 /DT390 and VEGF 121 rGel et al, wherein VEGF 121 And VEGF 165 Only plays the role of a targeting molecule, can not inhibit the generation of new blood vessels, and releases VEGF 121 And VEGF 165 Also has the effect of promoting neogenesisAngiogenesis; in addition, DT390 toxin has strong immunogenicity, poor curative effect after multiple administrations and causes severe vascular leakage reaction; the used rGEL toxin is wild type Gelonin, and has low solubility and biological activity, so that the method has a plurality of defects. The angiogenesis inhibitor and the angiogenesis disruptor both play a role by inhibiting angiogenesis or disrupting existing angiogenesis through a single mechanism, are also single targets, and do not play dual roles of the angiogenesis inhibitor and the disruptor.
Disclosure of Invention
In view of one or more of the problems of the prior art, one aspect of the present invention is to provide a fusion toxin VEGF 165b /mGEL, the fusion toxin VEGF 165b /mGEL comprises VEGF 165 Inhibitory splice isoforms VEGF 165b And the Gelonin mutant mGEL can simultaneously inhibit the generation of new vessels and destroy a new vessel network aiming at new vessel dependent diseases.
The difference between the amino acid sequence of the mGEL of the Gelonin mutant and the amino acid sequence of the natural Gelonin is as follows: lys10, Cys44 and Cys50 of the amino acid sequence of the natural Gelonin are mutated into Ser10, Ala44 and Ala50 respectively in the amino acid sequence of the Gelonin mutant mGEL, and the amino acid residue of the Gelonin mutant mGEL is shown as the amino acid sequence from the 171-417(247aa) position of the amino terminal of the amino acid sequence shown as SEQ ID NO:1 in the sequence table.
The fusion toxin VEGF 165b the/mGEL further comprises an endoplasmic reticulum localization sequence located at the carboxy terminus of the Gelonin mutant mGEL; optionally, the amino acid residue sequence of the endoplasmic reticulum positioning sequence is shown as a sequence SEQ ID NO: 5, respectively.
The fusion toxin VEGF 165b /mGEL further comprises a linker peptide or analogue thereof for linking to the VEGF 165 Inhibitory splice isoforms VEGF 165b And Gelonin mutant mGEL; optionally, the amino acid residue sequence of the connecting peptide is shown as SEQ ID NO: 3, respectively.
The fusion toxin VEGF 165b The amino acid residue sequence of/mGEL is one of the following amino acid residue sequences:
1) SEQ ID NO: 1;
2) and (2) mixing the sequences shown in SEQ ID NO:1 through substitution, deletion or addition of one to ten amino acid residues, and has the functions of VEGFR specificity, angiogenesis inhibition and endothelial cell killing of new blood vessels.
In another aspect of the invention, there is provided the fusion toxin VEGF 165b Encoding gene of/mGEL (VEGF) 165b /mGEL), in particular, the coding gene (VEGF) 165b /mGEL) is one of the following nucleotide sequences:
1) SEQ ID NO: 2;
2) (ii) encoding the amino acid sequence of SEQ ID NO: 1;
3) and SEQ ID NO: 2 has more than 90 percent of homology, VEGFR specificity, and the nucleotide sequence has the functions of inhibiting the generation of new vessels and killing endothelial cells of the new vessels;
4) under high stringency conditions, the polypeptide can be compared with SEQ ID NO: 2, and 2, or a nucleotide sequence which hybridizes to the nucleotide sequence shown in the figure.
The invention also provides a recombinant expression vector pDSS-VEGF 165b /mGEL, the recombinant expression vector pDSS-VEGF 165b /mGEL comprises the above-mentioned coding gene (VEGF) 165b /mGEL) for expressing the fusion toxin VEGF 165b /mGEL。
In still another aspect, the present invention provides a transgenic cell line or a host bacterium comprising the above-mentioned coding gene (VEGF) 165b /mGEL) or the recombinant expression vector described above for the fusion toxin VEGF described above 165b /mGEL。
In still another aspect of the present invention, there is provided a therapeutic agent for a neovascular dependent disease comprising the fusion toxin VEGF described above 165b /mGEL or the above-mentioned coding gene (VEGF) 165b /mGEL)；
Optionally, the therapeutic agent for a neovascular dependence disease further comprises one or more of: pharmaceutically acceptable carrier, diluent, excipient, filler, adhesive, wetting agent, disintegrant, absorption enhancer, and surfactant.
The above-mentioned neovascular dependent diseases include, but are not limited to, malignant tumors, ocular neovascular diseases.
In still another aspect, the invention provides a recombinant expression of the fusion toxin VEGF 165b A method of/mGEL comprising the steps of:
1) constructing the transgenic cell line or the host bacterium, and culturing the transgenic cell line or the host bacterium;
2) separating and purifying protein from culture medium or cells of transgenic cell line or host bacteria to obtain fusion toxin VEGF 165b /mGEL。
The method specifically comprises the following steps:
a) construction of a vector containing the above-described coding Gene (VEGF) 165b /mGEL) recombinant expression vector pDSS-VEGF 165b /mGEL；
b) Subjecting the recombinant expression vector pDSS-VEGF 165b the/mGEL is transformed into a transgenic cell line or a host bacterium and is cultured and expressed to obtain a fusion protein DSS-VEGF 165b /mGEL；
c) Excision of the fusion protein DSS-VEGF with the tool enzyme ULP1 165b DSS label of/mGEL, purifying to obtain fusion toxin VEGF 165b /mGEL；
Preferably, the tool enzyme ULP1 and the fusion protein DSS-VEGF in step c) 165b The dosage proportion relation of/mGEL is as follows: 1: (100- > 150); further preferably 1: 100.
Fusion toxin VEGF provided based on the technical scheme 165b mGEL has double functions of a neovascular inhibitor and a destructive agent, and is prepared from a targeting molecule-recombinant human vascular endothelial growth factor VEGF 165 Inhibitory splice isoforms VEGF 165b And an effector molecule, Gelonin mutant (mGEL), wherein VEGF 165b Is not only a VEGF antagonistAnd VEGFR targeting molecules: inhibition of VEGF function and neovascularization by competitive binding to VEGFR; meanwhile, the fusion toxin is brought into the endothelial cells of the new vessels by identifying VEGFR and endocytosis mechanism, the toxin molecule mGEL is released and is positioned to the rough endoplasmic reticulum through a C-terminal KDEL motif, and the synthesis of cell protein is inhibited, thereby destroying the existing new vessel network. Moreover, the fusion toxin has simple expression condition, is easy to purify and is suitable for industrial production. The fusion toxin can be used as an active ingredient to prepare medicines for treating various angiogenesis-dependent diseases such as malignant tumors (such as lung cancer, gastrointestinal cancer and the like) and neovascular eye diseases (such as macular degeneration), can play an important role in the fields of medicine and biological pharmacy, and has wide application prospect.
Drawings
FIG. 1 shows DSS-VEGF 165b GEL electrophoresis of GEL expression and purification in E.coli Origami (DE 3);
FIG. 2 shows DSS-VEGF 165b The expression and purification of the gel electrophoretogram of/mGEL in E.coli Origami (DE 3);
FIG. 3 is a diagram of the expression and purification gel electrophoresis of GST-ULP1 in E.coli;
FIG. 4 shows DSS-VEGF 165b The expression, purification and enzyme digestion of/mGEL identify the gel electrophoresis picture;
FIG. 5 shows DSS tag excision and VEGF 165b GEL electrophoresis image of GEL purification;
FIG. 6 shows DSS-VEGF 165b Expression purification of/mGEL, DSS tag excision and VEGF 165b a/mGEL purified gel electrophoresis image;
FIG. 7 shows VEGF 165b The cytotoxicity curve of GEL fusion toxin to PAE/KDR;
FIG. 8 shows VEGF 165b Cytotoxicity profiles of/mGEL fusion toxin versus PAE/KDR.
Detailed Description
The invention aims to provide a multi-target solution for treating the angiogenesis-dependent diseases, so that the multi-target solution has the dual functions of inhibiting angiogenesis and destroying a angiogenesis network.
An object of the present invention is toProvides a recombinant human vascular endothelial growth factor VEGF 165b Inhibitory splice isoforms VEGF 165b The fusion toxin with Gelonin mutant (mGEL) of Gelonin is named VEGF 165b /mGEL comprising VEGF 165 Inhibitory splice isoforms VEGF 165b And the Gelonin mutant mGEL can simultaneously inhibit the generation of new blood vessels and destroy new blood vessel networks aiming at new blood vessel dependent diseases.
Specifically, the recombinant human vascular endothelial growth factor VEGF is connected to the amino terminal (N-terminal) of the Gelonin mutant through a connecting peptide 165 Inhibitory splice isoforms VEGF 165b The fusion toxin is obtained, and the carboxyl terminal (C-terminal) of the fusion toxin has an endoplasmic reticulum localization sequence. The fusion toxin is a novel protein with double functions of a neovascular inhibitor and a neovascular damaging agent. Wherein:
VEGF 165b is a known recombinant human vascular endothelial growth factor VEGF 165 The inhibitory splice isomer is a VEGF antagonist and a VEGFR targeting molecule, and has the functions of inhibiting the proliferation of neovascular endothelial cells and the generation of new blood vessels and targeting VEGFR.
The Gelonin mutant (mGEL) is a mutant protein of natural Gelonin, which is an I-type ribosome inactivating protein existing in white tree seeds, can act on 28S rRNA on the ribosome large subunit of a mammal nucleus, generates an adenine-removing effect, destroys a ribosome structure, inhibits protein translation, and participates in the regulation of apoptosis. According to the invention, Lys10, Cys44 and Cys50 of natural Gelonin amino acid are respectively mutated into Ser10, Ala44 and Ala50 to reduce protein disulfide mismatch, improve soluble expression and improve the killing effect of fusion toxin on target cells, so that mGEL can be used as a toxin molecule to inhibit cell protein synthesis and destroy the existing new blood vessel network.
In order to position the toxin molecule mGEL to the rough endoplasmic reticulum of the endothelial cells of the new blood vessels, an endoplasmic reticulum positioning sequence is arranged at the carboxyl end (C-end) of the mGEL, the endoplasmic reticulum positioning sequence is a KDEL motif, and the amino acid residue sequence of the endoplasmic reticulum positioning sequence can be shown as a sequence SEQ ID NO: 5, the nucleotide sequence of the coding gene can be shown as SEQ ID NO: and 6.
Use of linker peptides for VEGF 165b The carboxy terminus (C-terminus) of (C) is linked to the amino terminus (N-terminus) of the mGEL. The choice of linker peptide is manifold, for example, the amino acid residue sequence may be as shown in SEQ ID NO: 3, the nucleotide sequence of the coding gene can be shown as SEQ ID NO: 4, respectively. The linker peptide may be replaced by an analogue thereof, which differs from the linker peptide by either an amino acid sequence, a modified form which does not affect the sequence, or both. These polypeptides include natural or induced genetic variants. Induced variants can be obtained by various techniques, such as random mutagenesis by irradiation or exposure to mutagens, site-directed mutagenesis, or other known molecular biology techniques. Analogs also include analogs having amino acid residues other than the naturally occurring L-amino acid residues (e.g., D-amino acids), as well as analogs having non-naturally occurring or synthetic amino acids.
In particular, the fusion toxin VEGF 165b the/mGEL is one of the following amino acid residue sequences:
1) SEQ ID NO: 1;
2) and (2) mixing the sequences shown in SEQ ID NO:1 through the substitution, deletion or addition of one to ten amino acid residues, and has the functions of VEGFR specificity, angiogenesis inhibition and angiogenesis network disruption.
SEQ ID NO:1 consists of 421 amino acid residues, and the 1 st to 165 th (165aa) amino acid residues from the amino terminal are recombinant human vascular endothelial growth factor VEGF 165 Inhibitory splice isoforms VEGF 165b The 166-170(5aa) amino acid residue from the amino terminal is a connecting peptide, the 171-417(247aa) amino acid residue from the amino terminal is a Gelonin mutant mGEL, and the 417 (4aa) amino acid residue from the amino terminal is a rough endoplasmic reticulum positioning signal sequence.
Further, in one aspect, the fusion toxin VEGF 165b Polypeptide fragments, derivatives and analogues of/mGEL also belong to the invention, which interact with VEGF 165b the/mGEL has the same biological function or activity, wherein the polypeptide fragment is defined as: 1) polypeptides substituted with one or more conserved or non-conserved amino acid residues (preferably conserved amino acid residues), and such substituted amino acid residues may or may not be encoded by the genetic code; 2) polypeptides having a substituent group in one or more amino acid residues; 3) a polypeptide formed by fusing a mature polypeptide to another compound; 4) fusion polypeptides can be produced by fusing an additional amino acid sequence to the polypeptide sequence (e.g., to purify the sequence of the polypeptide, or to a fusion toxin of an antibody fragment or other antigen-ligand sequence), or by fusing a nucleic acid sequence (or portion thereof) encoding another polypeptide to the nucleic acid sequence (or portion thereof) of the invention to obtain the coding sequence for the fusion polypeptide, and expressing the coding sequence for the fusion polypeptide. Such techniques for producing fusion polypeptides are well known in the art and include ligating the coding sequences encoding the polypeptides so that they are in frame and expression of the fusion polypeptide is under the control of the same promoter and terminator.
Fusion toxin VEGF 165b Derivatives of/mGEL refer to the use of VEGF in the invention 165b And fusion toxin constructed by fusing other toxin molecules.
VEGF 165b Analogues of/mGEL with VEGF 165b The difference in/mGEL may be a difference in amino acid sequence, a difference in modified form that does not affect the sequence, or both. The analogs include natural or induced genetic variants. Induced variants can be obtained by various techniques, such as random mutagenesis by irradiation or exposure to mutagens, site-directed mutagenesis, or other known molecular biological techniques. Analogs also include analogs having amino acid residues other than the naturally occurring L-amino acid residues (e.g., D-amino acids), as well as analogs having non-naturally occurring or synthetic amino acids. It is to be understood that the amino acid residue sequence of the fusion toxin of the present invention is not limited to the representative sequences exemplified above.
Further, in another aspect, the fusion toxin VEGF 165b the/mGEL may also be a VEGF modified or modified to increase its anti-proteolytic or solubility properties 165b a/mGEL polypeptide. Modified (generally without altering primary structure) forms include: 1) chemically derivatized forms of the polypeptide in vivo or in vitro, such as acetylated or carboxylated; 2) glycosylation, such as those produced by glycosylation modifications in the synthesis and processing of the polypeptide or in further processing steps, which can be accomplished by exposing the polypeptide to an enzyme that effects glycosylation (e.g., mammalian glycosylase or deglycosylase); 3) having a sequence of phosphorylated amino acid residues (e.g., phosphotyrosine, phosphoserine, phosphothreonine).
Gene encoding the above fusion toxin (VEGF) 165b /mGEL) also belongs to the invention, the gene is one of the following nucleotide sequences:
1) SEQ ID NO: 2;
2) encoding the amino acid sequence shown in SEQ ID NO: 1;
3) and SEQ ID NO: 2 has more than 90 percent of homology, VEGFR specificity, and the nucleotide sequence has the functions of inhibiting the generation of new vessels and killing endothelial cells of the new vessels;
4) under high stringency conditions with SEQ ID NO: 2, and 2, or a nucleotide sequence which hybridizes to the nucleotide sequence shown in the figure.
The high stringency conditions are those in which the membrane is washed after hybridization with a solution containing 0.1 XSSPE (or 0.1 XSSC), 0.1% SDS at 65 ℃.
SEQ ID NO: 2 consists of 1263 bases, the coding sequence of which is the 1 st to 1131 st bases from the 5' end, and codes the nucleotide sequence of SEQ ID NO:1, coding a recombinant human vascular endothelial growth factor VEGF from 1 to 495 th base of 5' end 165 Inhibitory splice isoforms VEGF 165b The 496-510 th base from the 5 ' end encodes the connecting peptide, the 511-1251 th base from the 5 ' end encodes the gelonin mGEL, and the 12 th base from the 5 ' end encodes the gelonin mGELBases 52-1263 encode signals for localization of endoplasmic reticulum.
Encoding the fusion toxin VEGF of the invention 165b the/mGEL polynucleotide may be in DNA form or RNA form. The form of DNA includes cDNA or synthetic DNA, which may be single-stranded or double-stranded, and may be either the coding strand or the non-coding strand.
Further, encoding the fusion toxin VEGF of the present invention 165b Variants of the polynucleotides of the/mGEL, which encode and fuse the toxin VEGF 165b the/mGEL has the same amino acid sequence of the polypeptide or polypeptide fragments, analogues and derivatives. The variants of the polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants, and may include substitution variants, deletion variants, and insertion variants. As is known in the art, an allelic variant is a substitution of a polynucleotide, which may be a substitution, deletion, or insertion of one or more nucleotides, without substantially altering the function of the polypeptide encoded thereby.
Containing the Gene of the invention (VEGF) 165b /mGEL), transgenic cell lines and host bacteria.
Another objective of the invention is to provide a method for recombinant expression of the fusion toxin VEGF 165b The preparation method of/mGEL is to use VEGF containing fusion toxin 165b /mGEL coding gene recombinant expression vector transformation or transduction host cell, culture of host cell, separation and purification of protein from culture medium or cell, obtaining fusion toxin VEGF 165b /mGEL。
The method comprises the following steps: VEGF containing fusion toxin 165b The recombinant expression vector of the coding gene of mGEL is fusion toxin VEGF 165b The coding gene of/mGEL or its variant gene is inserted into a recombinant expression vector, Xba I restriction site is added at the upstream of the coding gene, and Not I restriction site is added at the downstream. The starting vector for constructing the recombinant expression vector can be any one of bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenovirus, retrovirus or other vectors which are well known in the art and can express foreign genes.The starting vectors include, but are not limited to: expression vectors based on the T7 promoter for expression in bacteria, vectors for expression in mammalian cells and baculovirus-derived vectors for expression in insect cells. In general, any plasmid and vector can be used as long as they can replicate and are stable in the host. An important feature of the starting vector is that it usually contains a replication site, a promoter, a marker gene and translation control elements. The starting carrier preferably comprises an expression carrier containing disulfide bond isomerase DsbC-ubiquitin-like protein modification molecule SUMO fusion protein DsbC-SUMO (DSS for short), named as pDSS carrier, the carrier is based on pET carrier, and the amino acid residue sequence of the DsbC-SUMO fusion protein is shown as SEQ ID NO: 7, and the nucleotide sequence of the coding gene is shown as SEQ ID NO: shown in fig. 8. DsbC-SUMO can promote the formation of protein disulfide bonds and the repair of mismatched disulfide bonds in bacterial cytoplasm, and promote the correct folding and soluble expression of fusion proteins.
VEGF containing fusion toxin constructed by taking pDSS carrier as starting carrier 165b The recombinant expression vector of the coding gene of the mGEL is named as pDSS-VEGF 165b and/mGEL. Recombinant expression vector pDSS-VEGF 165b The fusion protein expressed by the mGEL in the host cell or host bacterium has a DSS label, and the fusion protein is named DSS-VEGF 165b The amino acid sequence of the/mGEL is shown as SEQ ID NO. 9 in the sequence table, and the nucleotide sequence for coding the amino acid sequence is shown as SEQ ID NO. 10 in the sequence table. The DSS tag can be excised by using a tool enzyme ULP1 to finally obtain fusion toxin VEGF with natural N-terminal 165b /mGEL。
The recombinant expression vector pDSS-VEGF can be constructed by methods well known to those skilled in the art 165b mGEL, such as in vitro recombinant DNA technology, DNA synthesis technology and in vivo recombinant technology (Sambrook, et al Molecular cloning, a Laboratory Manual. Cold spring harbor Laboratory. New York, 1989). The fusion toxin VEGF 165b The DNA sequence of the gene encoding/mGEL can be operably linked to an appropriate promoter in an expression vector to direct mRNA synthesis. The promoter may be: lac or trp promoter of Escherichia coli, phageSomatic promoters, retroviruses and other known promoters which control the expression of genes in prokaryotic or eukaryotic cells or viruses. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
In addition, the recombinant expression vector pDSS-VEGF 165b the/mGEL may also contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as the dihydrofolate reductase gene, neomycin resistance gene, and the Green Fluorescent Protein (GFP) gene for eukaryotic cells, or the tetracycline or ampicillin resistance gene for E.coli, among others. Fusion toxin VEGF of the invention 165b When the gene encoding mGEL is expressed in a higher eukaryotic cell, the transcription can be enhanced by using a recombinant expression vector pDSS-VEGF 165b An enhancer sequence is inserted into/mGEL. Enhancers are cis-acting elements of DNA, usually 10-300 base pairs in length, that act on a promoter to increase transcription of a gene. Such as the SV40 enhancer on the late side of the replication origin at about 100-270 bp in length, the polyoma enhancer or adenovirus enhancer on the late side of the replication origin, and the like.
In this method, the transformed or transduced host cell may be a prokaryotic cell, such as a bacterial cell; lower eukaryotic cells, such as yeast cells; higher eukaryotic cells, such as mammalian cells. Representative examples are: escherichia coli, streptomycete; bacterial cells of salmonella typhimurium; eukaryotic cells such as yeast, plant cells; insect cells such as Drosophila S2 or Sf 9; CHO, COS, 293 cells or Bowes melanoma cells.
The recombinant expression vector pDSS-VEGF can be expressed by conventional techniques well known to those skilled in the art 165b mGEL transformation of host cells, culture of transformants, inducible expression of the protein of interest (i.e., fusion toxin VEGF) 165b /mGEL) and separating and purifying the target protein.
Culturing the fusion toxin VEGF with the dual functions of inhibiting the generation of new blood vessels and destroying the network of the new blood vessels 165b The culture medium and culture conditions of the host cell of the encoding gene of the mGEL can be both culture initiationThe culture medium and the culture conditions of the host.
Use of fusion toxin VEGF 165b The invention also provides a medicament for treating angiogenesis-dependent diseases, including malignant tumors (such as lung cancer and gastrointestinal cancer) and neovascular eye diseases (such as wet macular degeneration). The active component of the medicine comprises the fusion toxin VEGF 165b /mGEL or a gene encoding the same.
When the active ingredient in the medicament for treating the new vessel dependent diseases is fusion toxin VEGF 165b When encoding gene of mGEL, the fusion toxin VEGF 165b The gene encoding/mGEL may be present in a eukaryotic expression vector.
If necessary, one or more pharmaceutically acceptable carriers can be added into the medicine. The carrier includes diluent, excipient, filler, adhesive, wetting agent, disintegrating agent, absorption enhancer, surfactant, adsorption carrier, etc. which are conventional in the pharmaceutical field.
The medicine of the present invention may be prepared into injection, freeze dried powder, etc. The medicaments in various dosage forms can be prepared according to the conventional method in the pharmaceutical field.
The methods used in the following examples are conventional unless otherwise specified, and specific procedures can be found in: molecular Cloning: A Laboratory Manual (Sambrook, J., Russell, David W., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, NY, Cold Spring Harbor).
The percentage concentration is a mass/volume (W/V) percentage concentration or a volume/volume (V/V) percentage concentration unless otherwise specified.
The primers, DNA sequence synthesis and DNA sequence determination were performed by Nanjing Kingsrey Biotech.
The various biomaterials described in the examples are obtained by way of experimental acquisition for the specific purpose disclosed and should not be construed as limiting the source of the biomaterials of the present invention. In fact, the sources of the biological materials used are wide, and any biological material that can be obtained without violating the law and ethics can be used instead as suggested in the examples; in industrial practice, various cells derived from mammals such as rat, mouse, pig or human are isolated, and include those obtained from cell banks or commercially available, prepared according to the teachings of the prior art, and induced by known methods from a variety of commercially available stem cells.
The embodiments are provided to assist understanding of the present invention, but the scope of the present invention is not limited to the following embodiments.
Example 1 fusion toxin VEGF 165b Expression and purification of mGEL in Escherichia coli
Recombinant expression vector pDSS-VEGF 165b GEL and pDSS-VEGF 165b Construction of/mGEL
The DSS-VEGF was synthesized in whole gene by Nanjing Kingsrey Biotech Co., Ltd, with codon optimization according to the preference of Escherichia coli 165b GEL and DSS-VEGF 165b mGEL gene and construction of expression vector pDSS-VEGF 165b GEL and pDSS-VEGF 165b /mGEL。
DSS-VEGF 165b The nucleotide sequence of mGEL is shown as SEQ ID NO:10, SEQ ID NO:10 consists of 2342 bases and encodes a polypeptide having the sequence shown in SEQ ID NO:9, wherein the 1 st to 6 th bases from the 5 ' -end are Xba I enzyme cutting sites, the 43 th to 1065 th bases from the 5 ' -end encode DSS labels, and the 1066-1560 th bases from the 5 ' -end encode recombinant human vascular endothelial growth factor VEGF 165 Inhibitory splice isoforms VEGF 165b The 1561-1575 base from the 5 ' -end encodes the connecting peptide, the 1576-2316 base from the 5 ' -end encodes the gelonin mutant mGEL, the 2317-2328 base from the 5 ' -end encodes the endoplasmic reticulum localization signal, the 2329-2334 base from the 5 ' -end is the stop codon, and the 2335-2342 base from the 5 ' -end is the Not I restriction site.
DSS-VEGF 165b The nucleotide sequence of the/GEL is shown as SEQ ID NO: 14, SEQ ID NO: 14 consists of 2342 bases and encodes a polypeptide having the sequence shown in SEQ ID NO: 13, wherein the 1 st to 6 th bases from the 5 ' -end are Xba I enzyme cutting sites, the 43 th to 1065 th bases from the 5 ' -end encode DSS labels, and the 1066 th and 1560 th bases from the 5 ' -end encode recombinant human vascular endothelial growth factor VEGF 165 Inhibitory splice isoforms VEGF 165b The 1561-1575 th base from the 5 ' -end encodes the connecting peptide, 1576-2316 th base from the 5 ' -end encodes the wild type gelonin GEL, 2317-2328 th base from the 5 ' -end encodes the endoplasmic reticulum localization signal, 2329-2334 th base from the 5 ' -end is the stop codon, and 2335-2342 th base from the 5 ' -end is the Not I restriction site.
Secondly, construction of recombinant expression vector pGEX-ULP1
The ULP1 gene was synthesized from the entire gene by Nanjing Kinsley Biotechnology company according to the codon preference of Escherichia coli, and an expression vector pGEX-ULP1 was constructed. The nucleotide sequence is shown as SEQ ID NO: 12, SEQ ID NO: 12 consists of 677 bases and encodes a polypeptide having the sequence shown in SEQ ID NO: 11, or a pharmaceutically acceptable salt thereof. The 1-6 bases from the 5 'end are BamH I enzyme cutting sites, the 7-663 bases from the 5' end encode ULP1, the 664-669 bases from the 5 'end are stop codons, and the 670-677 bases from the 5' end are Not I enzyme cutting sites.
Three, DSS-VEGF 165b /GEL、DSS-VEGF 165b Expression of/mGEL and ULP1 in E.coli
The specific expression method comprises the following steps:
(1) pDSS-VEGF constructed by the first step and the second step 165b /GEL、pDSS-VEGF 165b The plasmid mGEL and pGEX-ULP1 were transformed into Origimi (DE3) competent bacteria, respectively, and cultured at 37 ℃ for 16-20 hours. A single colony was inoculated into 10mL of LB medium (containing carbenicillin 200. mu.g/mL, kanamycin 50. mu.g/mL and tetracycline 25. mu.g/mL), and cultured overnight at 37 ℃ at 200 rpm.
(2) 10mL of overnight culture was transferred to 1L of LB medium (containing carbenicillin 200. mu.g/mL, Calif.)Natamycin 50. mu.g/mL and tetracycline 25. mu.g/mL), cultured at 37 ℃ and 200rpm to OD 600 ≈0.4～0.6。
(3) IPTG was added to a final concentration of 0.25mM (250. mu.l of 1M IPTG solution was added), the culture was continued overnight at 16 ℃ and 180rpm, and the bacteria were harvested by centrifugation at 6000rpm for 5 minutes.
Four, VEGF 165b GEL and VEGF 165b Purification of/mGEL
(1) Purification of DSS-VEGF Using Ni-Sepharose FF 165b /GEL、DSS-VEGF 165b The mGEL fusion protein: the bacterial pellets of both were resuspended in binding buffer (50mM Tris. HCl, 300mM NaCl, 20mM imidazole, pH8.0) at a ratio of 1:20, sonicated in ice bath (power 600W, 5 seconds each, 10 seconds apart, 20 minutes), centrifuged at 12000rpm for 60 minutes at 4 ℃ and the supernatant was collected. The HisTrapFF nickel column (1ml pre-packed column) was equilibrated with 5 column volumes of binding buffer (50mM Tris. HCl, 300mM NaCl, 20mM imidazole, pH 8.0). Loading on a column at a flow rate of 1 mL/min; the heteroproteins were eluted with 5 column volumes of wash solution (50mM Tris. HCl, pH8.0, 300mM NaCl, 40mM imidazole). The target protein was eluted with 50mM Tris-HCl, 300mM NaCl, 200mM imidazole (pH 8.0).
For DSS-VEGF respectively 165b GEL and DSS-VEGF 165b The expression and purification of/mGEL in E.coli Origami (DE3) was examined by gel electrophoresis (12% SDS-PAGE), the results are shown in FIGS. 1 and 2, where FIG. 1 is DSS-VEGF 165b Results of detection of the expression and purification of GEL in Escherichia coli Origami (DE3), lanes 1-5 in FIG. 1 are respectively shown as: lane 1 molecular weight standards; lane 2 is whole ultrasonic lysis; lanes 3, 4 are ultrasonication supernatants; lane 5 is the passage; lane 6 is eluted DSS-VEGF 165b a/GEL; FIG. 2 shows DSS-VEGF 165b The results of the detection of the expression and purification of/mGEL in E.coli Origami (DE3), lanes 1-5 in FIG. 2 are shown as: lane 1 is whole ultrasonic lysis; lane 2 is the lysis supernatant; lane 3 is the permeate; lane 4 shows eluted DSS-VEGF 165b (ii)/mGEL; lane 5 is molecular weight standard. Visible, DSS-VEGF 165b GEL and DSS-VEGF 165b The molecular weight of the/mGEL target protein is about 85kD, and the soluble DSS-VE in the thalli lysis supernatantGF 165b The expression level of/mGEL is obviously higher than that of DSS-VEGF 165b The expression level of GEL.
(2) GST-ULP1 purification Using GST HP: the bacterial pellet was resuspended in buffer A (10mM Na) at 1:20 2 HPO 4 ， 1.8mM KH 2 PO 4 140mM NaCl, 2.7mM KCl) was sonicated in an ice bath (power 600W, 5 seconds each, 10 seconds apart, 20 minutes), centrifuged at 12000rpm for 60 minutes at 4 ℃ and the supernatant was collected. After the 5 times column volume buffer A column is balanced, 1ml/min sample is loaded, buffer A washes impurities, the flow rate is 5ml/min, 5 column volumes. ULP1 protein was eluted with buffer B (50mM TrisCl, 10mM reduced glutathione, pH8.0) at a flow rate of 5ml/min, 3 bed volumes were collected and examined by gel electrophoresis, as shown in FIG. 3, wherein each lane is represented as: lane 1 molecular weight standards; lane 2 is whole ultrasonic lysis; lane 3 is the lysis supernatant; lane 4 is the crossing fluid; lane 5 is eluted GST-ULP 1.
(3) Determination of enzyme digestion system: (iii) use of GST-ULP1 obtained in step (2) above to DSS-VEGF obtained in step (1) above 165b The enzyme was cleaved with the aid of a different cleavage system (50mM Tris-HCl, 300mM NaCl, 200mM imidazole (pH8.0) buffer) at 8 ℃ overnight. As shown in FIG. 4, for DSS-VEGF 165b The expression, purification and cleavage results of/mGEL were examined by gel electrophoresis (12% SDS-PAGE), in which lanes 1-4 represent DSS-VEGF 165b Expression purification of/mGEL, lanes 5-13 show different cleavage systems (where approximately DSS-VEGF is contained per 100. mu.l cleavage system) 165b 120 μ g/mGEL fusion protein) of DSS-VEGF 165b The enzyme cutting identification result of/mGEL, wherein M represents a molecular weight standard. Visible, DSS-VEGF 165b the/mGEL is cut by ULP1 enzyme to obtain two fragments: fusion protein of interest VEGF 165b the/mGEL and DSS labels, and the different enzyme systems have different enzyme cutting effects, as can be seen from FIG. 4, when the tool enzyme ULP1 is compared with DSS-VEGF 165b When the dosage ratio of the mGEL fusion protein is about 1:150, the enzyme digestion efficiency can reach more than 90 percent; when the dosage ratio is 1:100, the enzyme digestion effect is better, and DSS-VEGF can be fully utilized 165b The DSS tag is excised from the/mGEL fusion protein.
(4) DSS labelExcision and VEGF 165b GEL and VEGF 165b Purification of mGEL: each 1. mu.g of ULP1 enzyme-digested 100. mu.g of fusion protein (DSS-VEGF) 165b /GEL or DSS-VEGF 165b /mGEL), 8 ℃ overnight. The cleavage products were diluted 1:3 with 50mM Tris Cl, pH8.0, applied to QFF column (50mM Tris HCl, 100mM NaCl, pH8.0 equilibrated), the permeate was collected, applied to SPFF column (50mM Tris HCl, 100mM NaCl, pH8.0 equilibrated) and washed for 5 column volumes. 50mM Tris-HCl, 300mM NaCl, pH8.0 respectively elute the fusion protein of interest VEGF 165b GEL and VEGF 165b and/mGEL. The results of 12% SDS-PAGE electrophoresis of the two samples are shown in FIGS. 5 and 6, where FIG. 5 shows the DSS tag excision and VEGF 165b The results of the GEL purification assay, shown in FIG. 5 as lanes 1-3: lane 1 is DSS-VEGF 165b The result of enzyme digestion of GEL by ULP 1; lane 2 is VEGF 165b The result after GEL reduction electrophoresis (the loading buffer solution contains beta-mercaptoethanol); lane 3 is VEGF 165b Results of GEL non-reduction (no beta-mercaptoethanol in loading buffer); m is a molecular weight standard. FIG. 6 shows DSS-VEGF 165b Expression purification of/mGEL, DSS tag excision and VEGF 165b The results of the/mGEL purification assay, shown in FIG. 6 as lanes 1-10: lane 1 molecular weight standards; lane 2 is whole ultrasonic lysis; lane 3 is the sonicated supernatant; lane 4 is the crossing fluid; lane 5 eluted protein; lane 6 shows the cleavage result; lane 7 is 1:3 dilution result; lane 8 is Q-column pass results; lane 9 is SP column crossing results; lane 10 shows VEGF eluted from SP column 165b and/mGEL. Visible DSS-VEGF 165b GEL and DSS-VEGF 165b After Ni-affinity chromatography, label removal and ion exchange chromatography are carried out on/mGEL, VEGF with higher purity is respectively obtained 165b GEL and VEGF 165b the/mGEL fusion toxin has a molecular weight of about 48kD, and VEGF is shown by the results of the enzyme cleavage in FIGS. 5 and 6 165b The yield of the/mGEL fusion toxin is far higher than that of VEGF 165b The amount of/GEL fusion toxin obtained indicates that mutations in the mGEL sequence do increase soluble expression.
Example 2 VEGF 165b /GEL、VEGF 165b /mGEL fusion toxin vs VEGFR 2 KDR positive cell PACytotoxicity of E/KDR (proffered by professor Chunchun of university of Beijing university's institute of Life sciences)
This example used VEGF obtained in example 1 above 165b GEL and VEGF 165b The mGEL fusion toxin is used for respectively detecting the toxic effect of the mGEL fusion toxin on PAE/KDR cells, and the specific method comprises the following steps:
1) dilution of PAE/KDR cells in logarithmic growth phase to 1.5X 10 4 Perml, add to 96-well plates, 200. mu.l per well (3000 cells/well) (first row without cells), 37 ℃ 5% CO 2 The incubation was carried out overnight. VEGF dilution in 96-well plates at 1:5 gradient 165b The initial concentration was 1. mu.M/mGEL, and the final volume was 200. mu.l/well. Pouring out the culture medium from the culture well, adding fusion toxin (first row with culture medium and second row without toxin) at 37 deg.C and 5% CO 2 Culturing for 24 and 48 hours respectively.
2) The medium was decanted from the cell culture wells and 100 μ l of 0.5% crystal violet solution (in 20% methanol) was added, incubated for 30 minutes at room temperature, washed off the dye and air dried.
3) Mu.l of Sorenson's buffer (0.1M sodium citrate, pH 4.2, 50% ethanol) was added, incubated at room temperature for 60-90 minutes, and the absorbance was measured at 630 nm.
4) And (3) measuring the absorbance value (OD value) of each hole, and calculating the survival rate according to a formula: (mean OD value of experimental wells/mean OD value of negative control wells) × 100%, and a cell viability curve was plotted.
Synchronous detection of VEGF in the same manner as above 165b Toxic effects of GEL fusion toxin on PAE/KDR cells.
As shown in FIGS. 7 and 8 (the abscissa represents the concentration of fusion toxin and the ordinate represents the cell viability), VEGF was found from the respective curves 165b GEL and VEGF 165b /mGEL vs VEGFR 2 IC50 of/KDR positive cell PAE/KDR is 0.56nM and 0.1nM respectively, VEGF can be seen 165b GEL and VEGF 165b /mGEL fusion toxin vs VEGFR 2 The vascular endothelial cells PAE/KDR with high KDR expression have specific cytotoxic effect, and VEGF 165b The cytotoxicity of/mGEL is obviously higher than that of VEGF 165b Cytotoxicity of GEL.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments described above, or equivalents may be substituted for elements thereof. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Sequence listing
<110> Ningbo Defanghua Biotechnology Ltd
Changeable grandchild
Shao Shuai
<120> fusion toxin VEGF165b/mGEL and coding gene and application thereof
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 421
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His His Glu Val Val Lys
1 5 10 15
Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr Leu
20 25 30
Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys
35 40 45
Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp Glu
50 55 60
Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile Thr Met Gln Ile
65 70 75 80
Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser Phe
85 90 95
Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg
100 105 110
Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His Leu Phe
115 120 125
Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr Asp Ser
130 135 140
Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys Arg Ser
145 150 155 160
Leu Thr Arg Lys Asp Gly Gly Gly Gly Ser Gly Leu Asp Thr Val Ser
165 170 175
Phe Ser Thr Ser Gly Ala Thr Tyr Ile Thr Tyr Val Asn Phe Leu Asn
180 185 190
Glu Leu Arg Val Lys Leu Lys Pro Glu Gly Asn Ser His Gly Ile Pro
195 200 205
Leu Leu Arg Lys Lys Ala Asp Asp Pro Gly Lys Ala Phe Val Leu Val
210 215 220
Ala Leu Ser Asn Asp Asn Gly Gln Leu Ala Glu Ile Ala Ile Asp Val
225 230 235 240
Thr Ser Val Tyr Val Val Gly Tyr Gln Val Arg Asn Arg Ser Tyr Phe
245 250 255
Phe Lys Asp Ala Pro Asp Ala Ala Tyr Glu Gly Leu Phe Lys Asn Thr
260 265 270
Ile Lys Thr Arg Leu His Phe Gly Gly Ser Tyr Pro Ser Leu Glu Gly
275 280 285
Glu Lys Ala Tyr Arg Glu Thr Thr Asp Leu Gly Ile Glu Pro Leu Arg
290 295 300
Ile Gly Ile Lys Lys Leu Asp Glu Asn Ala Ile Asp Asn Tyr Lys Pro
305 310 315 320
Thr Glu Ile Ala Ser Ser Leu Leu Val Val Ile Gln Met Val Ser Glu
325 330 335
Ala Ala Arg Phe Thr Phe Ile Glu Asn Gln Ile Arg Asn Asn Phe Gln
340 345 350
Gln Arg Ile Arg Pro Ala Asn Asn Thr Ile Ser Leu Glu Asn Lys Trp
355 360 365
Gly Lys Leu Ser Phe Gln Ile Arg Thr Ser Gly Ala Asn Gly Met Phe
370 375 380
Ser Glu Ala Val Glu Leu Glu Arg Ala Asn Gly Lys Lys Tyr Tyr Val
385 390 395 400
Thr Ala Val Asp Gln Val Lys Pro Lys Ile Ala Leu Leu Lys Phe Val
405 410 415
Asp Lys Asp Glu Leu
420
<210> 2
<211> 1263
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gcgccgatgg cggagggtgg cggccagaac catcacgagg ttgtgaaatt tatggacgtt 60
tatcaacgta gctattgcca cccgatcgaa accctggtgg acattttcca ggaatatccg 120
gatgagatcg aatacatctt taaaccgagc tgcgtgccgc tgatgcgctg cggtggctgc 180
tgcaatgacg agggtctgga atgcgttccg accgaagaga gcaacatcac catgcagatt 240
atgcgtatta agccgcatca aggccagcat atcggtgaaa tgagcttcct gcagcacaac 300
aaatgcgagt gccgtccgaa gaaagaccgt gcgcgtcaag agaacccgtg cggtccgtgc 360
agcgagcgtc gcaagcacct gttcgttcaa gacccgcaga cctgcaaatg cagctgcaag 420
aacaccgaca gccgttgcaa agcgcgtcaa ctggaactga atgaacgtac ctgccgtagc 480
ctgacccgta aggacggcgg cggcggtagc ggtctggaca ccgtgagctt cagcaccagc 540
ggcgcgacct atatcaccta cgttaacttc ctgaatgagc tgcgtgttaa gctgaaaccg 600
gaaggtaata gccacggtat tccgctgctg cgcaaaaagg cggacgatcc gggcaaagcg 660
tttgttctgg tggcgctgag caatgacaac ggccaactgg cggagattgc gatcgacgtt 720
accagcgtgt atgtggtggg ttaccaagtt cgcaatcgta gctacttctt caaggatgcg 780
ccggatgcgg cgtatgaggg tctgttcaag aacaccatca agacccgtct gcattttggc 840
ggtagctacc cgagcctgga aggtgaaaaa gcgtaccgtg aaaccaccga cctgggtatc 900
gaaccgctgc gtattggcat caagaagctg gacgagaacg cgatcgacaa ctacaaaccg 960
accgagattg cgagcagcct gctggttgtg atccagatgg ttagcgaggc ggcgcgtttt 1020
accttcattg agaaccagat ccgcaacaat ttccaacaac gcattcgccc ggcgaataac 1080
accatcagcc tggagaataa atggggtaaa ctgagcttcc aaatccgtac cagcggtgcg 1140
aacggcatgt ttagcgaagc ggtggaactg gagcgtgcga atggcaagaa gtattacgtg 1200
accgcggtgg accaagtgaa gccgaagatt gcgctgctga agtttgtgga taaagatgag 1260
ctg 1263
<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Gly Gly Gly Gly Ser
1 5
<210> 4
<211> 15
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ggcggcggcg gtagc 15
<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Lys Asp Glu Leu
1
<210> 6
<211> 12
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
aaagatgagc tg 12
<210> 7
<211> 341
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Met Arg Gly Ser His His His His His His Ser Ser Gly Asp Asp Ala
1 5 10 15
Ala Ile Gln Gln Thr Leu Ala Lys Met Gly Ile Lys Ser Ser Asp Ile
20 25 30
Gln Pro Ala Pro Val Ala Gly Met Lys Thr Val Leu Thr Asn Ser Gly
35 40 45
Val Leu Tyr Ile Thr Asp Asp Gly Lys His Ile Ile Gln Gly Pro Met
50 55 60
Tyr Asp Val Ser Gly Thr Ala Pro Val Asn Val Thr Asn Lys Met Leu
65 70 75 80
Leu Lys Gln Leu Asn Ala Leu Glu Lys Glu Met Ile Val Tyr Lys Ala
85 90 95
Pro Gln Glu Lys His Val Ile Thr Val Phe Thr Asp Ile Thr Cys Gly
100 105 110
Tyr Cys His Lys Leu His Glu Gln Met Ala Asp Tyr Asn Ala Leu Gly
115 120 125
Ile Thr Val Arg Tyr Leu Ala Phe Pro Arg Gln Gly Leu Asp Ser Asp
130 135 140
Ala Glu Lys Glu Met Lys Ala Ile Trp Cys Ala Lys Asp Lys Asn Lys
145 150 155 160
Ala Phe Asp Asp Val Met Ala Gly Lys Ser Val Ala Pro Ala Ser Cys
165 170 175
Asp Val Asp Ile Ala Asp His Tyr Ala Leu Gly Val Gln Leu Gly Val
180 185 190
Ser Gly Thr Pro Ala Val Val Leu Ser Asn Gly Thr Leu Val Pro Gly
195 200 205
Tyr Gln Pro Pro Lys Asp Met Lys Glu Phe Leu Asp Glu His Gln Lys
210 215 220
Met Thr Ser Gly Lys Gly Ser Thr Ser Gly Ser Gly His His His His
225 230 235 240
His His Gly Gly Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu
245 250 255
Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser
260 265 270
Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu
275 280 285
Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp
290 295 300
Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr
305 310 315 320
Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg
325 330 335
Glu Gln Ile Gly Gly
340
<210> 8
<211> 1023
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
atgcgtggta gccatcatca tcatcatcat agcagcggcg acgacgcggc gattcaacaa 60
accctggcga aaatgggcat caagagcagc gacatccagc cggcgccggt tgcgggcatg 120
aaaaccgtgc tgaccaacag cggcgtgctg tacatcaccg acgatggcaa gcatatcatc 180
caaggcccga tgtatgacgt gagcggcacc gcgccggtga acgttaccaa taagatgctg 240
ctgaaacagc tgaacgcgct ggaaaaggag atgatcgttt acaaagcgcc gcaggaaaaa 300
cacgtgatta ccgtttttac cgacattacc tgcggctatt gccataaact gcatgagcaa 360
atggcggatt acaatgcgct gggtatcacc gttcgctacc tggcgtttcc gcgtcaaggt 420
ctggacagcg atgcggagaa agagatgaaa gcgatctggt gcgcgaaaga caaaaacaag 480
gcgttcgatg acgtgatggc gggcaaaagc gttgcgccgg cgagctgcga cgttgatatt 540
gcggaccatt acgcgctggg cgtgcaactg ggtgtgagcg gcaccccggc ggtggttctg 600
agcaacggca ccctggttcc gggttatcaa ccgccgaagg acatgaagga gtttctggac 660
gaacaccaga agatgaccag cggcaaaggt agcaccagcg gtagcggcca tcatcaccac 720
catcatggtg gcagcgatag cgaggtgaat caggaagcga agccggaagt gaaaccggaa 780
gtgaagccgg aaacccacat taacctgaaa gtgagcgatg gtagcagcga aatctttttc 840
aaaatcaaga aaaccacccc gctgcgtcgc ctgatggagg cgttcgcgaa gcgtcagggt 900
aaagaaatgg acagcctgcg tttcctgtac gacggtattc gcattcaggc ggaccaaacc 960
ccggaagacc tggacatgga agacaatgat atcattgagg cgcatcgtga gcagattggt 1020
ggt 1023
<210> 9
<211> 762
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Met Arg Gly Ser His His His His His His Ser Ser Gly Asp Asp Ala
1 5 10 15
Ala Ile Gln Gln Thr Leu Ala Lys Met Gly Ile Lys Ser Ser Asp Ile
20 25 30
Gln Pro Ala Pro Val Ala Gly Met Lys Thr Val Leu Thr Asn Ser Gly
35 40 45
Val Leu Tyr Ile Thr Asp Asp Gly Lys His Ile Ile Gln Gly Pro Met
50 55 60
Tyr Asp Val Ser Gly Thr Ala Pro Val Asn Val Thr Asn Lys Met Leu
65 70 75 80
Leu Lys Gln Leu Asn Ala Leu Glu Lys Glu Met Ile Val Tyr Lys Ala
85 90 95
Pro Gln Glu Lys His Val Ile Thr Val Phe Thr Asp Ile Thr Cys Gly
100 105 110
Tyr Cys His Lys Leu His Glu Gln Met Ala Asp Tyr Asn Ala Leu Gly
115 120 125
Ile Thr Val Arg Tyr Leu Ala Phe Pro Arg Gln Gly Leu Asp Ser Asp
130 135 140
Ala Glu Lys Glu Met Lys Ala Ile Trp Cys Ala Lys Asp Lys Asn Lys
145 150 155 160
Ala Phe Asp Asp Val Met Ala Gly Lys Ser Val Ala Pro Ala Ser Cys
165 170 175
Asp Val Asp Ile Ala Asp His Tyr Ala Leu Gly Val Gln Leu Gly Val
180 185 190
Ser Gly Thr Pro Ala Val Val Leu Ser Asn Gly Thr Leu Val Pro Gly
195 200 205
Tyr Gln Pro Pro Lys Asp Met Lys Glu Phe Leu Asp Glu His Gln Lys
210 215 220
Met Thr Ser Gly Lys Gly Ser Thr Ser Gly Ser Gly His His His His
225 230 235 240
His His Gly Gly Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu
245 250 255
Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser
260 265 270
Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu
275 280 285
Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp
290 295 300
Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr
305 310 315 320
Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg
325 330 335
Glu Gln Ile Gly Gly Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His
340 345 350
His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His
355 360 365
Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile
370 375 380
Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly
385 390 395 400
Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn
405 410 415
Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln Gly Gln His Ile
420 425 430
Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys
435 440 445
Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg
450 455 460
Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys
465 470 475 480
Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu
485 490 495
Arg Thr Cys Arg Ser Leu Thr Arg Lys Asp Gly Gly Gly Gly Ser Gly
500 505 510
Leu Asp Thr Val Ser Phe Ser Thr Ser Gly Ala Thr Tyr Ile Thr Tyr
515 520 525
Val Asn Phe Leu Asn Glu Leu Arg Val Lys Leu Lys Pro Glu Gly Asn
530 535 540
Ser His Gly Ile Pro Leu Leu Arg Lys Lys Ala Asp Asp Pro Gly Lys
545 550 555 560
Ala Phe Val Leu Val Ala Leu Ser Asn Asp Asn Gly Gln Leu Ala Glu
565 570 575
Ile Ala Ile Asp Val Thr Ser Val Tyr Val Val Gly Tyr Gln Val Arg
580 585 590
Asn Arg Ser Tyr Phe Phe Lys Asp Ala Pro Asp Ala Ala Tyr Glu Gly
595 600 605
Leu Phe Lys Asn Thr Ile Lys Thr Arg Leu His Phe Gly Gly Ser Tyr
610 615 620
Pro Ser Leu Glu Gly Glu Lys Ala Tyr Arg Glu Thr Thr Asp Leu Gly
625 630 635 640
Ile Glu Pro Leu Arg Ile Gly Ile Lys Lys Leu Asp Glu Asn Ala Ile
645 650 655
Asp Asn Tyr Lys Pro Thr Glu Ile Ala Ser Ser Leu Leu Val Val Ile
660 665 670
Gln Met Val Ser Glu Ala Ala Arg Phe Thr Phe Ile Glu Asn Gln Ile
675 680 685
Arg Asn Asn Phe Gln Gln Arg Ile Arg Pro Ala Asn Asn Thr Ile Ser
690 695 700
Leu Glu Asn Lys Trp Gly Lys Leu Ser Phe Gln Ile Arg Thr Ser Gly
705 710 715 720
Ala Asn Gly Met Phe Ser Glu Ala Val Glu Leu Glu Arg Ala Asn Gly
725 730 735
Lys Lys Tyr Tyr Val Thr Ala Val Asp Gln Val Lys Pro Lys Ile Ala
740 745 750
Leu Leu Lys Phe Val Asp Lys Asp Glu Leu
755 760
<210> 10
<211> 2342
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
tctagaaata attttgttta actttaagaa ggagatatac atatgcgtgg tagccatcat 60
catcatcatc atagcagcgg cgacgacgcg gcgattcaac aaaccctggc gaaaatgggc 120
atcaagagca gcgacatcca gccggcgccg gttgcgggca tgaaaaccgt gctgaccaac 180
agcggcgtgc tgtacatcac cgacgatggc aagcatatca tccaaggccc gatgtatgac 240
gtgagcggca ccgcgccggt gaacgttacc aataagatgc tgctgaaaca gctgaacgcg 300
ctggaaaagg agatgatcgt ttacaaagcg ccgcaggaaa aacacgtgat taccgttttt 360
accgacatta cctgcggcta ttgccataaa ctgcatgagc aaatggcgga ttacaatgcg 420
ctgggtatca ccgttcgcta cctggcgttt ccgcgtcaag gtctggacag cgatgcggag 480
aaagagatga aagcgatctg gtgcgcgaaa gacaaaaaca aggcgttcga tgacgtgatg 540
gcgggcaaaa gcgttgcgcc ggcgagctgc gacgttgata ttgcggacca ttacgcgctg 600
ggcgtgcaac tgggtgtgag cggcaccccg gcggtggttc tgagcaacgg caccctggtt 660
ccgggttatc aaccgccgaa ggacatgaag gagtttctgg acgaacacca gaagatgacc 720
agcggcaaag gtagcaccag cggtagcggc catcatcacc accatcatgg tggcagcgat 780
agcgaggtga atcaggaagc gaagccggaa gtgaaaccgg aagtgaagcc ggaaacccac 840
attaacctga aagtgagcga tggtagcagc gaaatctttt tcaaaatcaa gaaaaccacc 900
ccgctgcgtc gcctgatgga ggcgttcgcg aagcgtcagg gtaaagaaat ggacagcctg 960
cgtttcctgt acgacggtat tcgcattcag gcggaccaaa ccccggaaga cctggacatg 1020
gaagacaatg atatcattga ggcgcatcgt gagcagattg gtggtgcgcc gatggcggag 1080
ggtggcggcc agaaccatca cgaggttgtg aaatttatgg acgtttatca acgtagctat 1140
tgccacccga tcgaaaccct ggtggacatt ttccaggaat atccggatga gatcgaatac 1200
atctttaaac cgagctgcgt gccgctgatg cgctgcggtg gctgctgcaa tgacgagggt 1260
ctggaatgcg ttccgaccga agagagcaac atcaccatgc agattatgcg tattaagccg 1320
catcaaggcc agcatatcgg tgaaatgagc ttcctgcagc acaacaaatg cgagtgccgt 1380
ccgaagaaag accgtgcgcg tcaagagaac ccgtgcggtc cgtgcagcga gcgtcgcaag 1440
cacctgttcg ttcaagaccc gcagacctgc aaatgcagct gcaagaacac cgacagccgt 1500
tgcaaagcgc gtcaactgga actgaatgaa cgtacctgcc gtagcctgac ccgtaaggac 1560
ggcggcggcg gtagcggtct ggacaccgtg agcttcagca ccagcggcgc gacctatatc 1620
acctacgtta acttcctgaa tgagctgcgt gttaagctga aaccggaagg taatagccac 1680
ggtattccgc tgctgcgcaa aaaggcggac gatccgggca aagcgtttgt tctggtggcg 1740
ctgagcaatg acaacggcca actggcggag attgcgatcg acgttaccag cgtgtatgtg 1800
gtgggttacc aagttcgcaa tcgtagctac ttcttcaagg atgcgccgga tgcggcgtat 1860
gagggtctgt tcaagaacac catcaagacc cgtctgcatt ttggcggtag ctacccgagc 1920
ctggaaggtg aaaaagcgta ccgtgaaacc accgacctgg gtatcgaacc gctgcgtatt 1980
ggcatcaaga agctggacga gaacgcgatc gacaactaca aaccgaccga gattgcgagc 2040
agcctgctgg ttgtgatcca gatggttagc gaggcggcgc gttttacctt cattgagaac 2100
cagatccgca acaatttcca acaacgcatt cgcccggcga ataacaccat cagcctggag 2160
aataaatggg gtaaactgag cttccaaatc cgtaccagcg gtgcgaacgg catgtttagc 2220
gaagcggtgg aactggagcg tgcgaatggc aagaagtatt acgtgaccgc ggtggaccaa 2280
gtgaagccga agattgcgct gctgaagttt gtggataaag atgagctgta atgagcggcc 2340
gc 2342
<210> 11
<211> 219
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 11
Leu Val Pro Glu Leu Asn Glu Lys Asp Asp Asp Gln Val Gln Lys Ala
1 5 10 15
Leu Ala Ser Arg Glu Asn Thr Gln Leu Met Asn Arg Asp Asn Ile Glu
20 25 30
Ile Thr Val Arg Asp Phe Lys Thr Leu Ala Pro Arg Arg Trp Leu Asn
35 40 45
Asp Thr Ile Ile Glu Phe Phe Met Lys Tyr Ile Glu Lys Ser Thr Pro
50 55 60
Asn Thr Val Ala Phe Asn Ser Phe Phe Tyr Thr Asn Leu Ser Glu Arg
65 70 75 80
Gly Tyr Gln Gly Val Arg Arg Trp Met Lys Arg Lys Lys Thr Gln Ile
85 90 95
Asp Lys Leu Asp Lys Ile Phe Thr Pro Ile Asn Leu Asn Gln Ser His
100 105 110
Trp Ala Leu Gly Ile Ile Asp Leu Lys Lys Lys Thr Ile Gly Tyr Val
115 120 125
Asp Ser Leu Ser Asn Gly Pro Asn Ala Met Ser Phe Ala Ile Leu Thr
130 135 140
Asp Leu Gln Lys Tyr Val Met Glu Glu Ser Lys His Thr Ile Gly Glu
145 150 155 160
Asp Phe Asp Leu Ile His Leu Asp Cys Pro Gln Gln Pro Asn Gly Tyr
165 170 175
Asp Cys Gly Ile Tyr Val Cys Met Asn Thr Leu Tyr Gly Ser Ala Asp
180 185 190
Ala Pro Leu Asp Phe Asp Tyr Lys Asp Ala Ile Arg Met Arg Arg Phe
195 200 205
Ile Ala His Leu Ile Leu Thr Asp Ala Leu Lys
210 215
<210> 12
<211> 677
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
ggatccctgg tgccggagct gaacgaaaaa gacgatgacc aggttcaaaa ggcgctggcg 60
agccgtgaga acacccagct gatgaaccgt gataacatcg aaattaccgt gcgtgacttc 120
aaaaccctgg cgccgcgtcg ttggctgaac gataccatca tcgagttctt tatgaagtac 180
atcgaaaaga gcaccccgaa caccgtggcg tttaacagct tcttttacac caacctgagc 240
gagcgtggtt atcagggcgt tcgtcgttgg atgaagcgta agaaaaccca aatcgataaa 300
ctggacaaaa tcttcacccc gattaacctg aaccagagcc actgggcgct gggtatcatt 360
gatctgaaga aaaagaccat cggttacgtg gacagcctga gcaacggccc gaacgcgatg 420
agcttcgcga ttctgaccga tctgcaaaaa tatgttatgg aggaaagcaa gcacaccatc 480
ggtgaagatt ttgacctgat tcacctggat tgcccgcagc aaccgaacgg ttacgactgc 540
ggcatctatg tttgcatgaa caccctgtat ggcagcgcgg atgcgccgct ggatttcgac 600
tataaagacg cgattcgtat gcgtcgtttt atcgcgcacc tgattctgac cgacgcgctg 660
aagtaatgag cggccgc 677
<210> 13
<211> 762
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 13
Met Arg Gly Ser His His His His His His Ser Ser Gly Asp Asp Ala
1 5 10 15
Ala Ile Gln Gln Thr Leu Ala Lys Met Gly Ile Lys Ser Ser Asp Ile
20 25 30
Gln Pro Ala Pro Val Ala Gly Met Lys Thr Val Leu Thr Asn Ser Gly
35 40 45
Val Leu Tyr Ile Thr Asp Asp Gly Lys His Ile Ile Gln Gly Pro Met
50 55 60
Tyr Asp Val Ser Gly Thr Ala Pro Val Asn Val Thr Asn Lys Met Leu
65 70 75 80
Leu Lys Gln Leu Asn Ala Leu Glu Lys Glu Met Ile Val Tyr Lys Ala
85 90 95
Pro Gln Glu Lys His Val Ile Thr Val Phe Thr Asp Ile Thr Cys Gly
100 105 110
Tyr Cys His Lys Leu His Glu Gln Met Ala Asp Tyr Asn Ala Leu Gly
115 120 125
Ile Thr Val Arg Tyr Leu Ala Phe Pro Arg Gln Gly Leu Asp Ser Asp
130 135 140
Ala Glu Lys Glu Met Lys Ala Ile Trp Cys Ala Lys Asp Lys Asn Lys
145 150 155 160
Ala Phe Asp Asp Val Met Ala Gly Lys Ser Val Ala Pro Ala Ser Cys
165 170 175
Asp Val Asp Ile Ala Asp His Tyr Ala Leu Gly Val Gln Leu Gly Val
180 185 190
Ser Gly Thr Pro Ala Val Val Leu Ser Asn Gly Thr Leu Val Pro Gly
195 200 205
Tyr Gln Pro Pro Lys Asp Met Lys Glu Phe Leu Asp Glu His Gln Lys
210 215 220
Met Thr Ser Gly Lys Gly Ser Thr Ser Gly Ser Gly His His His His
225 230 235 240
His His Gly Gly Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu
245 250 255
Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser
260 265 270
Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu
275 280 285
Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp
290 295 300
Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr
305 310 315 320
Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg
325 330 335
Glu Gln Ile Gly Gly Ala Pro Met Ala Glu Gly Gly Gly Gln Asn His
340 345 350
His Glu Val Val Lys Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His
355 360 365
Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile
370 375 380
Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly
385 390 395 400
Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn
405 410 415
Ile Thr Met Gln Ile Met Arg Ile Lys Pro His Gln Gly Gln His Ile
420 425 430
Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys
435 440 445
Lys Asp Arg Ala Arg Gln Glu Asn Pro Cys Gly Pro Cys Ser Glu Arg
450 455 460
Arg Lys His Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys
465 470 475 480
Lys Asn Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu
485 490 495
Arg Thr Cys Arg Ser Leu Thr Arg Lys Asp Gly Gly Gly Gly Ser Gly
500 505 510
Leu Asp Thr Val Ser Phe Ser Thr Lys Gly Ala Thr Tyr Ile Thr Tyr
515 520 525
Val Asn Phe Leu Asn Glu Leu Arg Val Lys Leu Lys Pro Glu Gly Asn
530 535 540
Ser His Gly Ile Pro Leu Leu Arg Lys Lys Cys Asp Asp Pro Gly Lys
545 550 555 560
Cys Phe Val Leu Val Ala Leu Ser Asn Asp Asn Gly Gln Leu Ala Glu
565 570 575
Ile Ala Ile Asp Val Thr Ser Val Tyr Val Val Gly Tyr Gln Val Arg
580 585 590
Asn Arg Ser Tyr Phe Phe Lys Asp Ala Pro Asp Ala Ala Tyr Glu Gly
595 600 605
Leu Phe Lys Asn Thr Ile Lys Thr Arg Leu His Phe Gly Gly Ser Tyr
610 615 620
Pro Ser Leu Glu Gly Glu Lys Ala Tyr Arg Glu Thr Thr Asp Leu Gly
625 630 635 640
Ile Glu Pro Leu Arg Ile Gly Ile Lys Lys Leu Asp Glu Asn Ala Ile
645 650 655
Asp Asn Tyr Lys Pro Thr Glu Ile Ala Ser Ser Leu Leu Val Val Ile
660 665 670
Gln Met Val Ser Glu Ala Ala Arg Phe Thr Phe Ile Glu Asn Gln Ile
675 680 685
Arg Asn Asn Phe Gln Gln Arg Ile Arg Pro Ala Asn Asn Thr Ile Ser
690 695 700
Leu Glu Asn Lys Trp Gly Lys Leu Ser Phe Gln Ile Arg Thr Ser Gly
705 710 715 720
Ala Asn Gly Met Phe Ser Glu Ala Val Glu Leu Glu Arg Ala Asn Gly
725 730 735
Lys Lys Tyr Tyr Val Thr Ala Val Asp Gln Val Lys Pro Lys Ile Ala
740 745 750
Leu Leu Lys Phe Val Asp Lys Asp Glu Leu
755 760
<210> 14
<211> 2342
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
tctagaaata attttgttta actttaagaa ggagatatac atatgcgtgg cagccaccac 60
caccaccacc acagcagcgg tgacgatgcg gcgattcagc aaaccctggc gaaaatgggc 120
atcaagagca gcgatattca accggcgccg gttgcgggta tgaagaccgt gctgaccaac 180
agcggtgttc tgtacatcac cgacgatggc aaacacatca ttcaaggtcc gatgtatgac 240
gtgagcggca ccgcgccggt gaacgttacc aacaaaatgc tgctgaagca gctgaacgcg 300
ctggagaagg aaatgatcgt ttacaaggcg ccgcaagaaa aacacgtgat caccgttttc 360
accgatatta cctgcggcta ttgccacaaa ctgcacgagc agatggcgga ctacaacgcg 420
ctgggcatta ccgtgcgtta tctggcgttc ccgcgtcaag gtctggacag cgatgcggag 480
aaagaaatga aggcgatctg gtgcgcgaag gataaaaaca aggcgtttga cgatgttatg 540
gcgggcaaga gcgttgcgcc ggcgagctgc gatgtggata ttgcggacca ctatgcgctg 600
ggtgttcaac tgggcgtgag cggcaccccg gcggtggttc tgagcaacgg caccctggtt 660
ccgggttatc agccgccgaa agacatgaag gagtttctgg atgaacacca aaagatgacc 720
agcggcaaag gtagcaccag cggtagcggt caccaccacc accaccacgg tggcagcgat 780
agcgaggtga accaggaagc gaaaccggaa gtgaagccgg aagtgaaacc ggaaacccac 840
atcaacctga aggttagcga cggtagcagc gaaatcttct ttaagattaa gaaaaccacc 900
ccgctgcgtc gtctgatgga agcgttcgcg aagcgtcaag gcaaagagat ggacagcctg 960
cgttttctgt acgatggtat ccgtattcag gcggaccaaa ccccggaaga cctggatatg 1020
gaggacaacg atatcattga agcgcatcgt gagcagatcg gtggtgcgcc gatggcggaa 1080
ggtggcggtc aaaaccacca cgaggtggtt aagttcatgg atgtgtacca gcgtagctat 1140
tgccacccga tcgaaaccct ggttgatatt ttccaagagt acccggacga gatcgaatat 1200
atttttaaac cgagctgcgt gccgctgatg cgttgcggcg gttgctgcaa cgacgagggt 1260
ctggaatgcg ttccgaccga ggaaagcaac attaccatgc agatcatgcg tattaagccg 1320
caccagggcc aacacatcgg tgaaatgagc ttcctgcagc acaacaaatg cgagtgccgt 1380
ccgaagaaag accgtgcgcg tcaagaaaac ccgtgcggtc cgtgcagcga gcgtcgtaaa 1440
cacctgtttg tgcaggaccc gcagacctgc aagtgcagct gcaaaaacac cgacagccgt 1500
tgcaaggcgc gtcagctgga gctgaacgaa cgtacctgcc gtagcctgac ccgtaaagat 1560
ggcggtggcg gatccggcct ggacaccgtt agcttcagca ccaaaggtgc gacctacatt 1620
acctatgtga actttctgaa cgaactgcgt gttaaactga agccggaggg caacagccac 1680
ggtatcccgc tgctgcgtaa gaaatgcgac gatccgggca agtgcttcgt gctggttgcg 1740
ctgagcaacg ataacggtca gctggcggaa atcgcgattg acgtgaccag cgtttacgtg 1800
gttggctatc aagtgcgtaa ccgtagctac ttctttaaag acgcgccgga tgcggcgtat 1860
gagggtctgt tcaagaacac cattaaaacc cgtctgcact ttggcggtag ctacccgagc 1920
ctggagggtg aaaaggcgta tcgtgaaacc accgatctgg gcatcgagcc gctgcgtatc 1980
ggtattaaga aactggacga aaacgcgatc gataactaca aaccgaccga gattgcgagc 2040
agcctgctgg ttgtgatcca gatggttagc gaagcggcgc gtttcacctt tatcgagaac 2100
caaattcgta acaacttcca gcaacgtatc cgtccggcga acaacaccat tagcctggaa 2160
aacaaatggg gcaagctgag cttccagatt cgtaccagcg gcgcgaacgg catgtttagc 2220
gaggcggtgg agctggaacg tgcgaacggt aagaaatact atgtgaccgc ggttgaccaa 2280
gtgaaaccga agatcgcgct gctgaagttt gttgacaaag atgagctgta atgagcggcc 2340
gc 2342

Claims (11)

1. Fusion toxin VEGF 165b /mGEL, characterized in that the fusion toxin VEGF 165b /mGEL comprises VEGF 165 Inhibitory splice isoforms VEGF 165b The Gelonin mutant mGEL can inhibit the generation of new vessels and destroy a new vessel network aiming at new vessel dependent diseases;
the fusion toxin VEGF 165b The amino acid sequence of/mGEL is shown as SEQ ID NO:1 is shown.
2. The fusion toxin VEGF of claim 1 165b The coding gene of/mGEL is characterized in that the nucleotide sequence of the coding gene is one of the following nucleotide sequences:
1) SEQ ID NO: 2;
2) encoding the amino acid sequence of SEQ ID NO: 1.
3. A recombinant expression vector comprising the coding gene of claim 2 for expressing the fusion toxin VEGF of claim 1 165b /mGEL。
4. A transgenic cell line or host bacterium comprising the coding gene of claim 2 or the recombinant expression vector of claim 3 for expressing the fusion toxin VEGF of claim 1 165b /mGEL。
5. A therapeutic agent for a neovascular dependent disease, comprising the fusion toxin VEGF of claim 1 165b The gene encoding/mGEL or the gene of claim 2.
6. The therapeutic agent for a neovascular dependence disease according to claim 5, further comprising one or more of: pharmaceutically acceptable carrier, diluent, excipient, filler, adhesive, wetting agent, disintegrant, absorption enhancer, and surfactant.
7. The agent for treating a neovascular-dependent disease according to claim 5 or 6, wherein the neovascular-dependent disease includes a malignant tumor and an ocular neovascular disease.
8. A method for recombinantly expressing the fusion toxin VE of claim 1GF 165b A method of/mGEL comprising the steps of:
1) constructing a transgenic cell line or a host bacterium according to claim 4, and culturing the transgenic cell line or the host bacterium;
2) separating and purifying protein from culture medium or cells of transgenic cell line or host bacteria to obtain fusion toxin VEGF 165b /mGEL。
9. The method according to claim 8, characterized in that it comprises in particular the steps of:
a) constructing a recombinant expression vector containing the coding gene of claim 2;
b) transforming the recombinant expression vector into a transgenic cell line or a host bacterium, and carrying out culture expression to obtain a fusion protein DSS-VEGF 165b /mGEL；
c) Excision of the fusion protein DSS-VEGF with the tool enzyme ULP1 165b DSS label of/mGEL, purifying to obtain fusion toxin VEGF 165b /mGEL。
10. The method according to claim 9, wherein in step c) the tool enzyme ULP1 is fused to the fusion protein DSS-VEGF 165b The dosage proportion relation of/mGEL is 1: (100-150).
11. The method according to claim 10, wherein in step c) the tool enzyme ULP1 is fused to the fusion protein DSS-VEGF 165b The dosage proportion relation of/mGEL is 1: 100.
CN202010145502.9A 2020-03-05 2020-03-05 Fusion toxin VEGF 165b mGEL and its coding gene and application Active CN113354738B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010145502.9A CN113354738B (en) 2020-03-05 2020-03-05 Fusion toxin VEGF 165b mGEL and its coding gene and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010145502.9A CN113354738B (en) 2020-03-05 2020-03-05 Fusion toxin VEGF 165b mGEL and its coding gene and application

Publications (2)

Publication Number Publication Date
CN113354738A CN113354738A (en) 2021-09-07
CN113354738B true CN113354738B (en) 2022-09-09

Family

ID=77523556

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010145502.9A Active CN113354738B (en) 2020-03-05 2020-03-05 Fusion toxin VEGF 165b mGEL and its coding gene and application

Country Status (1)

Country Link
CN (1) CN113354738B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070349A (en) * 2007-05-22 2007-11-14 山西康宝生物制品股份有限公司 Fusion protein with function of selective killing endothelial cells in tumor neogenetic blood vessels and use thereof
WO2011017809A1 (en) * 2009-08-11 2011-02-17 The University Of British Columbia Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer
CN103865899A (en) * 2012-12-17 2014-06-18 山西康宝生物制品股份有限公司 Fusion toxin with specificity of VEGFR2/KDR acceptor, and coding gene and application thereof
CN103974711A (en) * 2011-11-28 2014-08-06 阿达梅德公司 Anticancer fusion protein
WO2014127211A1 (en) * 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
CN105646697A (en) * 2016-04-08 2016-06-08 新乡医学院 VEGF165b (vascular endothelial growth factor 165b) mutant as well as preparation method and application thereof
CN110546160A (en) * 2017-02-06 2019-12-06 奥里尼斯生物科学公司 Targeted chimeric proteins and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070349A (en) * 2007-05-22 2007-11-14 山西康宝生物制品股份有限公司 Fusion protein with function of selective killing endothelial cells in tumor neogenetic blood vessels and use thereof
WO2011017809A1 (en) * 2009-08-11 2011-02-17 The University Of British Columbia Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer
CN103974711A (en) * 2011-11-28 2014-08-06 阿达梅德公司 Anticancer fusion protein
CN103865899A (en) * 2012-12-17 2014-06-18 山西康宝生物制品股份有限公司 Fusion toxin with specificity of VEGFR2/KDR acceptor, and coding gene and application thereof
WO2014127211A1 (en) * 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
CN105646697A (en) * 2016-04-08 2016-06-08 新乡医学院 VEGF165b (vascular endothelial growth factor 165b) mutant as well as preparation method and application thereof
CN110546160A (en) * 2017-02-06 2019-12-06 奥里尼斯生物科学公司 Targeted chimeric proteins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Vascular-Targeting Fusion Toxin VEGF121/rGel Inhibits the Growth of Orthotopic Human Bladder Carcinoma Tumors;Khalid A. Mohamedali et al.;《Neoplasia》;20051031;第7卷(第10期);第912~920页 *

Also Published As

Publication number Publication date
CN113354738A (en) 2021-09-07

Similar Documents

Publication Publication Date Title
US6780843B2 (en) Sequence and method for genetic engineering of proteins with cell membrane translocating activity
US6639050B1 (en) Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
KR20140097529A (en) Anticancer fusion protein
US20060246539A1 (en) Protein production method utilizing yebF
JP2002513283A (en) RNA binding proteins and binding sites useful for expression of recombinant molecules
US20080280323A1 (en) Method for Producing Epidermal Growth Factor Using Fusion Proteins Comprising Fas-1 Domain
US20060252120A1 (en) Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20230093611A1 (en) Recombinant microalgae able to produce peptides, polypeptides or proteins of collagen, elastin and their derivatives in the chloroplast of microalgae and associated method thereof
JP4521270B2 (en) Polynucleotide and polypeptide encoded by the polynucleotide and involved in the synthesis of diketopiperazine derivatives
AU674741B2 (en) Methods and DNA expression systems for over-expression of proteins in host cells
CN113354738B (en) Fusion toxin VEGF 165b mGEL and its coding gene and application
JPH04504208A (en) Recombinant trichosanthin and coding sequence
JP4546089B2 (en) Fusion protein
KR20050028011A (en) Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
US20230146589A1 (en) Use of aprotinin as a carrier to produce a recombinant protein, polypeptide or peptide in algae
KR101634078B1 (en) Process for producing protein capable of forming inclusion body
CN115160422A (en) Salt-tolerant drought-resistant sweet potato related protein IbMYB44 as well as coding gene and application thereof
KR102000490B1 (en) Transformants for expressing flagellin protein derived from Salmonella sp. with improved solubility, preparation method and use thereof
US7223742B2 (en) Enhanced solubility of recombinant proteins
RU2325440C1 (en) RECOMBINANT PLASMID DNA pGG-1 CODING POLYPEPTIDE OF HUMAN PROINSULIN GLARGIN AND STRAIN OF BACTERIA ESCHERICHIA COLI BGG18-PRODUCER OF RECOMBINANT PROINSULIN GLARGIN
KR101902848B1 (en) Fusion flavonoid O-methyltransferase and use thereof
IL174588A (en) Methods of cleaving polypeptides
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
JPH04182498A (en) Polypeptide
KR102631925B1 (en) Development of novel fgf21 variants, production techniques and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 312000 floor 3, building 9-1, No. 21, Haitian Road, Lihai street, Yuecheng District, Shaoxing City, Zhejiang Province

Applicant after: Shaoxing defanghua Biotechnology Co.,Ltd.

Applicant after: Sun Hongyan

Applicant after: Shao Shuai

Address before: 315615 No. 166 Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province

Applicant before: Ningbo defanghua Biotechnology Co.,Ltd.

Applicant before: Sun Hongyan

Applicant before: Shao Shuai

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240329

Address after: 312000 1st floor, building 9-1, No. 21, Haitian Road, Lihai street, Yuecheng District, Shaoxing City, Zhejiang Province

Patentee after: Zhejiang Yuchang Biotechnology Co.,Ltd.

Country or region after: China

Patentee after: Sun Hongyan

Patentee after: Shao Shuai

Address before: 312000 floor 3, building 9-1, No. 21, Haitian Road, Lihai street, Yuecheng District, Shaoxing City, Zhejiang Province

Patentee before: Shaoxing defanghua Biotechnology Co.,Ltd.

Country or region before: China

Patentee before: Sun Hongyan

Patentee before: Shao Shuai